A 28-year-old man from Delhi is found to have a heterozygous TP53 mutation (Li-Fraumeni syndrome) on genetic screening performed after his sister was diagnosed with rhabdomyosarcoma at age 6. He is currently asymptomatic with normal imaging. What is the most appropriate next step?

Question

Accepted Answer

C. Initiate comprehensive surveillance protocol with 6-monthly clinical examination, annual whole-body MRI, and baseline chest/abdominal imaging. ## Li-Fraumeni Syndrome (LFS) Overview

Li-Fraumeni syndrome is an autosomal dominant cancer predisposition syndrome caused by germline TP53 mutations. TP53 is a critical tumor suppressor encoding the "guardian of the genome."

**Key Point:** TP53 mutations confer a lifetime cancer risk of ~90% in heterozygotes, with diverse malignancy types (breast, sarcoma, brain, adrenal, leukemia) and early age of onset.

## Surveillance Strategy for Asymptomatic TP53 Mutation Carriers

Once a TP53 mutation is identified, the standard of care is **intensive surveillance**, NOT chemoprevention or reassurance:

| Modality | Frequency | Rationale |
|----------|-----------|----------|
| Clinical examination | Every 3–6 months | Early detection of palpable masses |
| Whole-body MRI | Annual (or 6-monthly if high-risk family) | Detects soft-tissue and CNS tumors |
| Chest/abdominal imaging | Baseline + annual | Lung, liver, adrenal cancers |
| Dermatologic exam | Annual | Melanoma and other skin cancers |
| Colonoscopy | Age 40–50 onwards | Colorectal cancer screening |

**High-Yield:** The goal is early detection while tumors are still localized and surgically resectable. Surveillance does NOT prevent cancer but improves outcomes through stage-shift.

**Clinical Pearl:** TP53 carriers should AVOID unnecessary radiation (including CT scans when possible) because ionizing radiation increases cancer risk in this population — use MRI preferentially.

**Mnemonic:** LFS = **L**ifelong **F**requent **S**urveillance (not prophylactic treatment).

[cite:Robbins 10e Ch 7]

Answer

A. Reassure the patient that TP53 mutations are benign variants and no follow-up is needed

Answer

B. Prophylactic chemotherapy with doxorubicin to prevent tumor development

Answer

D. Recommend immediate total body irradiation to eliminate potential malignant clones

A 28-year-old man from Delhi is found to have a heterozygous TP53 mutation (Li-Fraumeni syndrome) on genetic screening performed after his sister was diagnosed with rhabdomyosarcoma at age 6. He is currently asymptomatic with normal imaging. What is the most appropriate next step?

Explanation

Li-Fraumeni Syndrome (LFS) Overview

Surveillance Strategy for Asymptomatic TP53 Mutation Carriers

Practice similar questions

Join our NEET PG community

Modality	Frequency	Rationale
Clinical examination	Every 3–6 months	Early detection of palpable masses
Whole-body MRI	Annual (or 6-monthly if high-risk family)	Detects soft-tissue and CNS tumors
Chest/abdominal imaging	Baseline + annual	Lung, liver, adrenal cancers
Dermatologic exam	Annual	Melanoma and other skin cancers
Colonoscopy	Age 40–50 onwards	Colorectal cancer screening